Clinical utility and patient considerations in the use of the sitagliptin–metformin combination in Chinese patients

References

• UnwinNGuariguataLWhitingDWeilCComplementary approaches to estimation of the global burden of diabetesLancet201237998251487148822521068
   PubMed Web of Science ®Google Scholar
• PanXRYangWYLiGWLiuJPrevalence of diabetes and its risk factors in China, 1994. National Diabetes Prevention and Control Cooperative GroupDiabetes Care19972011166416699353605
   PubMed Web of Science ®Google Scholar
• YangWLuJWengJChina National Diabetes and Metabolic Disorders Study GroupPrevalence of diabetes among men and women in ChinaN Engl J Med2010362121090110120335585
   PubMed Web of Science ®Google Scholar
• XuYWangLHeJ2010 China noncommunicable disease surveillance GroupPrevalence and control of diabetes in Chinese adultsJAMA2013310994895924002281
   PubMed Web of Science ®Google Scholar
• MaRCLinXJiaWCauses of type 2 diabetes in ChinaLancet Diabetes Endocrinol20142127014570147
   Web of Science ®Google Scholar
• Chinese Diabetes SocietyGuideline of prevention and treatment for type 2 diabetes patients in ChinaChina J Diabetes2014228243
   Google Scholar
• LinJDChenYLHsuCHBeta-cell function and insulin sensitivity at various degrees of glucose tolerance in Chinese subjectsDiabetes Res Clin Pract2013100339139723587481
   PubMed Web of Science ®Google Scholar
• HongJGuWQZhangYFThe interplay of insulin resistance and beta-cell dysfunction involves the development of type 2 diabetes in Chinese obesesEndocrine2007312939917873317
   PubMed Web of Science ®Google Scholar
• TuomiTSantoroNCaprioSCaiMWengJGroopLThe many faces of diabetes: a disease with increasing heterogeneityLancet201438399221084109424315621
   PubMed Web of Science ®Google Scholar
• YangWWengJEarly therapy for type 2 diabetes in ChinaLancet Diabetes Endocrinol20142127013670146
   Web of Science ®Google Scholar
• BiYZengLZhuDAssociation of beta-cell function and insulin sensitivity with fasting and 2-h plasma glucose in a large Chinese populationDiabetes Obes Metab201214217418021951345
   PubMed Web of Science ®Google Scholar
• CryerPEMinireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetesEndocrinology201215331039104822166985
   PubMed Web of Science ®Google Scholar
• FarhyLSMcCallALOptimizing reduction in basal hyperglucagonaemia to repair defective glucagon counterregulation in insulin deficiencyDiabetes Obes Metab2011Suppl 113314321824267
   PubMed Web of Science ®Google Scholar
• GerichJPathogenesis and management of postprandial hyperglycemia: role of incretin-based therapiesInt J Gen Med2013687789524403842
   PubMedGoogle Scholar
• ElrickHStimmlerLHladCJJrAraiYPlasma insulin response to oral and intravenous glucose administrationJ Clin Endocrinol Metab1964241076108214228531
   PubMed Web of Science ®Google Scholar
• LeeYSJunHSAnti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cellsMetabolism201463191924140094
   PubMed Web of Science ®Google Scholar
• PoucherSMCheethamSFrancisJZinkerBKirbyMVickersSPEffects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetesDiabetes Obes Metab2012141091892622564773
   PubMed Web of Science ®Google Scholar
• KimYSOhSHParkKSImproved outcome of islet transplantation in partially pancreatectomized diabetic mice by inhibition of dipeptidyl peptidase-4 with sitagliptinPancreas201140685586021747318
   PubMed Web of Science ®Google Scholar
• TakedaYFujitaYHonjoJReduction of both beta cell death and alpha cell proliferation by dipeptidyl peptidase-4 inhibition in a streptozotocin-induced model of diabetes in miceDiabetologia201255240441222072158
   PubMed Web of Science ®Google Scholar
• DruckerDJIncretin action in the pancreas: potential promise, possible perils, and pathological pitfallsDiabetes201362103316332323818527
   PubMed Web of Science ®Google Scholar
• UngerJRationale use of GLP-1 receptor agonists in patients with type 1 diabetesCurr Diab Rep201313566366823955813
   PubMed Web of Science ®Google Scholar
• TremblayAJLamarcheBDeaconCFWeisnagelSJCouturePEffects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetesMetabolism20146391141114825034387
   PubMed Web of Science ®Google Scholar
• McCormickLMKyddACReadPAChronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery diseaseCirc Cardiovasc Imaging20147227428124503784
   PubMed Web of Science ®Google Scholar
• ZengYLiCGuanMThe DPP-4 inhibitor sitagliptin attenuates the progress of atherosclerosis in apolipoprotein-E-knockout mice via AMPK- and MAPK-dependent mechanismsCardiovasc Diabetol2014133224490809
   PubMed Web of Science ®Google Scholar
• SharmaAKSharmaAKumariRSitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in ratsJ Biomed Res201226320021023554750
   PubMedGoogle Scholar
• Januvia^® (sitagliptin) tablets [prescribing information]Whitehouse Station, NJMerck & Co Inc Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021995s023lbl.pdfAccessed November 1, 2014
   Google Scholar
• GLUCOPHAGE^® (metformin hydrochloride) tablets, GLUCOPHAGE^® XR (metformin hydrochloride) extended-release tablets [prescribing information]Princeton, NJBristol-Myers Squibb Company Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,021202s016lbl.pdfAccessed November 1, 2014
   Google Scholar
• HermanGABergmanAYiBKipnesMSitagliptin Study 012 GroupTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin200622101939194717022853
   PubMed Web of Science ®Google Scholar
• FassADGershmanJAEfficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metforminAdv Ther201330433735323605247
   PubMed Web of Science ®Google Scholar
• WuDYMAWQWangLGEfficacy of dipeptidyl peptidase-4 inhibitor sitagliptin on patients with type 2 diabetes inadequately controlled with metformin aloneClinical Focus2011262017621764 Chinese.
   Google Scholar
• FanXXClinical efficacy of metformin combined with sitagliptin or pioglitazone in treatment of type 2 diabetes mellitusClin Med China2013291212951298 Chinese.
   Google Scholar
• LiangJJZouDJCost-effectiveness analysis of sitagliptin and pioglitazone in poorly controlled type 2 diabetes mellitus patients with oral metforminShanghai Med J2013365414417 Chinese.
   Google Scholar
• LiWHLinMZhangXJComparison on adding sitagliptin or glimepiride in poorly controlled overweight type 2 diabetes with oral metforminChin Hosp Pharm J20123210792794 Chinese.
   Google Scholar
• SunJLiSSJiangSQuanLEfficacy of sitagliptin controlled with metformin on patients with type 2 diabetes mellitusChinese J Prac Med20134019105106 Chinese.
   Google Scholar
• JiaoXMXuXPZhaoJLvXFClinical observation on treatment of newly diagnosed type 2 diabetes with sitagliptin and metforminClin Focus20132814448 Chinese.
   Google Scholar
• QuYZhangCLHuWJLiuMYHeRClinical observation on curative effect of sitagliptin, rosiglitazone combined with Metformin respectively in treatment of elderly type 2 diabetesProg Mod Biomed2013132140774080 Chinese.
   Google Scholar
• HuangBXClinical observation on treatment of newly diagnosed diabetes with sitagliptin and metforminNat Med Front China2011665859 Chinese.
   Google Scholar
• DuanLJZhangYJiangXEfficacy studies of sitagliptin combined with metformin in newly diagnosed type 2 diabetes patientsClin Med China2013294379382 Chinese.
   Google Scholar
• TrainaSGuthrieRSleeAThe impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetesPostgrad Med2014126371524918788
   PubMed Web of Science ®Google Scholar
• MontillaSMarchesiniGSammarcoAAIFA Anti-diabetics Monitoring GroupDrug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring RegistryNutr Metab Cardiovasc Dis201424121346135325300980
   PubMed Web of Science ®Google Scholar
• WangTGouZWangFMaMZhaiSDComparison of GLP-1 an alogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studiesPLoS One201498e10379825089625
   PubMed Web of Science ®Google Scholar
• AhrénBJohnsonSLStewartMHARMONY 3 Study GroupHARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metforminDiabetes Care20143782141214824898304
   PubMed Web of Science ®Google Scholar
• JungJAKakuKKimJHAdditive postprandial glucose-lowering effects of mitiglinide and sitagliptin in patients with type 2 diabetes mellitusAdv Ther201330111018112924249434
   PubMed Web of Science ®Google Scholar
• EijiKTadatakaHEffect of sitagliptin in type 1 or type 2 diabetic patients with absolute insulin deficiency: a 48 weeks observational studyBr J Med Med Res20133419101917
   Google Scholar
• ScheenAGliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitisExpert Opin Drug Saf201312454555723621381
   PubMed Web of Science ®Google Scholar
• IyerSNDrakeAJ3rdWestRLMendezCETanenbergRJCase report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatideEndocr Pract2012181e10e1322068258
   PubMedGoogle Scholar
• MondragonADavidssonDKyriakoudiSDivergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaPLoS One201498e10487325119717
   PubMed Web of Science ®Google Scholar
• FaillieJLBabaiSCrépinSFrench Pharmacovigilance Centers NetworkPancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance DatabaseActa Diabetol201451349149724352344
   PubMed Web of Science ®Google Scholar
• LiLShenJBalaMMIncretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studiesBMJ2014348g236624736555
   PubMed Web of Science ®Google Scholar
• PloskerGLSitagliptin: a review of its use in patients with type 2 diabetes mellitusDrugs201474222324224407560
   PubMed Web of Science ®Google Scholar
• MonamiMDicembriniIMannucciEDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsDiabetes Obes Metab2014161485623837679
   PubMed Web of Science ®Google Scholar
• FimognariFLPastorelliRIncalziRAPhenformin-induced lactic acidosis in an older diabetic patient: a recurrent drama (phenformin and lactic acidosis)Diabetes Care200629495095116567854
   PubMed Web of Science ®Google Scholar
• VeitchPCClifton-BlighRJLong-acting sulfonylureas – long-acting hypoglycaemiaMed J Aust20041802848514723592
   PubMed Web of Science ®Google Scholar
• RendellMAkturkHKTellaSHGlargine safety, diabetes and cancerExpert Opin Drug Saf201312224726323394441
   PubMed Web of Science ®Google Scholar
• KeatingGMInsulin detemir: a review of its use in the management of diabetes mellitusDrugs201272172255228723110609
   PubMed Web of Science ®Google Scholar
• HellerSMcCanceDRMoghissiENazeriAKordonouriODiversity in diabetes: the role of insulin aspartDiabetes Metab Res Rev2012281506121695769
   PubMed Web of Science ®Google Scholar
• VincentMNobécourtETreatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studiesDiabetes Metab201339429930523642642
   PubMed Web of Science ®Google Scholar
• Philis-TsimikasABrodMNiemeyerMOcampo FranciscoAMRothmanJInsulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use)Adv Ther201330660762223812875
   PubMed Web of Science ®Google Scholar
• YangWJiQZhuDBiphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugsDiabetes Care200831585285618268073
   PubMed Web of Science ®Google Scholar
• ParkesDGMaceKFTrautmannMEDiscovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1Expert Opin Drug Discov20138221924423231438
   PubMed Web of Science ®Google Scholar
• NauckMFridAHermansenKLong-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 studyDiabetes Obes Metab201315320421222985213
   PubMed Web of Science ®Google Scholar
• ChanJCZhangYNingGDiabetes in China: a societal solution for a personal challengeLancet Diabetes Endocrinol201421496997925218728
   PubMed Web of Science ®Google Scholar
• AraiKMaedaHSirabeSGlimepiride strongly enhances the glucose-lowering effect in triple oral antidiabetes therapy with sitagliptin and metformin for Japanese patients with type 2 diabetes mellitusDiabetes Technol Ther201315433534123480592
   PubMed Web of Science ®Google Scholar
• OsonoiTSaitoMTamasawaAIshidaHOsonoiYEffects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring in Japanese patients with type 2 diabetes: a prospective randomized studyExpert Opin Pharmacother201415101325133524866329
   PubMed Web of Science ®Google Scholar
• BarnettAHComplementing insulin therapy to achieve glycemic controlAdv Ther2013306556557
   Web of Science ®Google Scholar